These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8557544)

  • 1. Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon.
    DiGiovanni RL; Littlefield JM; Good RG
    J Am Osteopath Assoc; 1995 Oct; 95(10):572. PubMed ID: 8557544
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis.
    Kamata Y; Kamimura T; Iwamoto M; Minota S
    Clin Exp Dermatol; 2005 Jul; 30(4):451. PubMed ID: 15953103
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
    Marasini B; Massarotti M; Bottasso B; Coppola R; Del Papa N; Maglione W; Comina DP; Maioli C
    Scand J Rheumatol; 2004; 33(4):253-6. PubMed ID: 15370722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The vasoprostan treatment of patients with Raynaud's syndrome].
    Alekperov RT; Mach ES; Guseva NG
    Ter Arkh; 1997; 69(8):22-3. PubMed ID: 9381386
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
    Lamprecht P; Schnabel A; Gross WL
    Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
    [No Abstract]   [Full Text] [Related]  

  • 8. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue.
    Tsukamoto H; Nagasawa K
    Br J Rheumatol; 1991 Aug; 30(4):317. PubMed ID: 1863837
    [No Abstract]   [Full Text] [Related]  

  • 10. Sildenafil for the treatment of Raynaud's phenomenon.
    Heymann WR
    J Am Acad Dermatol; 2006 Sep; 55(3):501-2. PubMed ID: 16908357
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al.
    Lichtenstein JR
    Arthritis Rheum; 2003 Jan; 48(1):282-3; author reply 283. PubMed ID: 12528146
    [No Abstract]   [Full Text] [Related]  

  • 12. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2004 Dec; (12):1725-34. PubMed ID: 15865744
    [No Abstract]   [Full Text] [Related]  

  • 13. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2005 Jun; (13):1546-54. PubMed ID: 16135302
    [No Abstract]   [Full Text] [Related]  

  • 14. [A new peripheral vasodilator prostaglandin E1 in atherosclerosis of lower limb vessels and Raynaud disease].
    Kirichenko AA; Novichkova IuN; Zubkova LV; Ter-Gevondian NM; Nenakhova TV
    Klin Med (Mosk); 1991 Nov; 69(11):40-3. PubMed ID: 1808404
    [No Abstract]   [Full Text] [Related]  

  • 15. [Management of Raynaud's phenomenon].
    Boccalon H; Monin A; Reggy M
    Soins Cardiol; 1986 Apr; (38):27-9. PubMed ID: 3637023
    [No Abstract]   [Full Text] [Related]  

  • 16. [Spasm and Raynaud's phenomenon].
    Fiessinger JN
    Ann Cardiol Angeiol (Paris); 1981; 30(2):91-3. PubMed ID: 7259052
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of Raynaud's phenomenon].
    Levy Y; Shoenfeld Y
    Harefuah; 1993 Mar; 124(5):288-91. PubMed ID: 8098699
    [No Abstract]   [Full Text] [Related]  

  • 18. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2003 Jun; (9):1339-48. PubMed ID: 12967424
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 20. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.